620 related articles for article (PubMed ID: 27658789)
1. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
2. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
3. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
4. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
5. Translating cancer genomics for precision oncology in biliary tract cancers.
Haber PK; Sia D
Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu-directed therapy for biliary tract cancer.
Javle M; Churi C; Kang HC; Shroff R; Janku F; Surapaneni R; Zuo M; Barrera C; Alshamsi H; Krishnan S; Mishra L; Wolff RA; Kaseb AO; Thomas MB; Siegel AB
J Hematol Oncol; 2015 May; 8():58. PubMed ID: 26022204
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
11. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
12. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling.
Bridgewater JA; Goodman KA; Kalyan A; Mulcahy MF
Am Soc Clin Oncol Educ Book; 2016; 35():e194-203. PubMed ID: 27249723
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
Al Mahmasani L; Harding JJ; Abou-Alfa G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):643-657. PubMed ID: 38423933
[TBL] [Abstract][Full Text] [Related]
14. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
15. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
[TBL] [Abstract][Full Text] [Related]
16. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics of biliary tract cancer.
Sohal DP; Shrotriya S; Abazeed M; Cruise M; Khorana A
Crit Rev Oncol Hematol; 2016 Nov; 107():111-118. PubMed ID: 27823638
[TBL] [Abstract][Full Text] [Related]
18. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
